Cas9 News and Research

RSS

ESGCT Conference Takeaways: A specialty laboratory perspective

Discover the latest innovations in cell and gene therapy via Cerba Research's highlights of ESGCT.

From Cerba Research 22 Nov 2024

Small brain-penetrating molecule offers hope for treating aggressive brain tumors

Gliocidin selectively kills glioblastoma cells by inhibiting nucleotide synthesis, showing potential as a therapeutic option in combination with temozolomide.

21 Nov 2024

CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital.

20 Nov 2024

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

From MaxCyte, Inc. 13 Nov 2024

Key reason why some cancers do not respond to immunotherapy identified

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target for improved cancer treatments.

12 Nov 2024

CRISPR technology reveals essential noncoding RNAs in the human genome

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA to proteins.

7 Nov 2024

New targets identified for treating glioblastoma through genetic screen

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer.

4 Nov 2024

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

4 Nov 2024

New insights into cardiac defects in Myotonic Dystrophy Type 1

People with Myotonic Dystrophy Type 1 (DM1), the most common adult-onset form of muscular dystrophy, progressively lose muscle mass and strength in their lower legs, hands, neck and face.

29 Oct 2024

Researchers uncover key mechanisms of CRISPR gene editing

CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy.

28 Oct 2024

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024

Harnessing the power of miRNA for cancer diagnosis and treatment

This study is led by Dr. Shiwei Duan (Department of Clinical Medicine, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China). His team analyzed literature on miRNA, summarizing the close relationship between these small molecules and cancer. miRNA is a type of non-coding RNA that does not encode proteins, but can target more than 60% of human protein-coding genes.

15 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Université de Montréal gains access to ERS Genomics' CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

From ERS Genomics 1 Oct 2024

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems.

25 Sep 2024

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of insecticides, thus further increasing mosquito resistance and exposing the world to an elevated risk of mosquito-borne diseases.

23 Sep 2024

Enhanced TnpB protein offers new possibilities for gene editing

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known "gene scissor" but is much smaller and thus easier to transport into cells.

23 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024